Dysplasia

Ibex Introduces Galen Gastric, World's First AI-powered Solution for Gastrointestinal Cancer Diagnostics, at Maccabi Healthcare Services

Retrieved on: 
星期二, 八月 24, 2021
CTO, Dysplasia, Clinical research, Congress, Cancer, Stomach, HMO, Diagnosis, Maccabi Healthcare Services, Survival, Biobank, Innovation Center station, Innovation, Database, Efficiency, Physician, Prostate, Epidemiology, Man, Food, Research, Health, TEL, Stomach cancer, Marie Cassidy, AI, Intelligence, KSM, Data collection, Deep learning, Patient, Solution, Algorithm, List of pathologists, Breast, FDA, Quality control, Artificial intelligence, Woman, Oncology, Technology, Regulation of tobacco by the U.S. Food and Drug Administration, MD, Medical device, Medical imaging

However, a rise in cancer prevalence and advances in personalized medicine have resulted in growing diagnostic complexity that significantly increases pathologists' workloads.

Key Points: 
  • However, a rise in cancer prevalence and advances in personalized medicine have resulted in growing diagnostic complexity that significantly increases pathologists' workloads.
  • Ibex transforms cancer diagnosis by harnessing Strong AI and Machine Learning technology at an unprecedented scale.
  • Galen Gastric is an integrated diagnostics and quality control solution that supports pathologists in the detection of gastric cancer, dysplasia, H. pylori and other important clinical findings.
  • The solution is an addition to Galen Prostate and Galen Breast that have already been deployed at Maccabi Healthcare Services, as well as other labs worldwide, where they are used in everyday clinical practice.

FibroGen to Present at Upcoming Investor Conferences

Retrieved on: 
星期四, 五月 27, 2021
Branches of biology, Biology, Cell biology, Transcription factors, Hypoxia-inducible factor, Growth factors, CTGF, Myelodysplastic syndrome, Roxadustat, Hypoxia in fish, HIF, Dysplasia

A replay will be available for approximately 30 days.

Key Points: 
  • A replay will be available for approximately 30 days.
  • FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics.
  • The Company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs.
  • Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA).

Global Cervical Dysplasia Market (2021 to 2028) - Share, Size, Trends and Industry Analysis Report - ResearchAndMarkets.com

Retrieved on: 
星期四, 五月 6, 2021
General Health, Health, Oncology, Infectious causes of cancer, Cancer, Gynaecological cancer, Medical specialties, Clinical medicine, Histopathology, Oncology, Cervical cancer, Cervical intraepithelial neoplasia, Dysplasia

b'The "Cervical Dysplasia Market Share, Size, Trends, Industry Analysis Report, By Type; By End-Use, By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global cervical dysplasia market size is expected to reach USD 936.4 million by 2028 according to a new study.

Key Points: 
  • b'The "Cervical Dysplasia Market Share, Size, Trends, Industry Analysis Report, By Type; By End-Use, By Regions; Segment Forecast, 2021 - 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global cervical dysplasia market size is expected to reach USD 936.4 million by 2028 according to a new study.
  • The report gives a detailed insight into current market dynamics and provides analysis on future market growth.\nThe rising prevalence of cervical cancer and awareness regarding its early diagnosis is the key cervical dysplasia industry impacting factors.
  • National Cervical Cancer Coalition under government control was responsible to highlight issues related to disease and the importance of early diagnosis.
  • These government-supported initiatives are bound to increase awareness regarding disease screening and are anticipated to boost the market growth for cervical dysplasia.\n'

FibroGen to Report First Quarter 2021 Financial Results

Retrieved on: 
星期一, 五月 3, 2021
Medical specialties, Blood, Branches of biology, Anemias, Acetic acids, Myelodysplastic syndrome, Roxadustat, Dysplasia

b"SAN FRANCISCO, May 03, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2021 financial results on Monday, May 10 after the market close.

Key Points: 
  • b"SAN FRANCISCO, May 03, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its first quarter 2021 financial results on Monday, May 10 after the market close.
  • FibroGen will also conduct a conference call on that day at 5:00 p.m.
  • ET (2:00 p.m. PT) with the investment community to further detail the company's corporate and financial performance.\nInterested parties may access a live audio webcast of the conference call via the FibroGen website at https://fibrogen.gcs-web.com/events-and-presentations/events .
  • Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA).

INOVIO to Report First Quarter 2021 Financial Results on May 10, 2021

Retrieved on: 
星期二, 四月 27, 2021
Medicine, Oncology, Histopathology, Medical research, Medical specialties, Health sciences, Inovio Pharmaceuticals, Precancerous condition, Anal dysplasia, Dysplasia, Carcinoma in situ, INO-4800

b'PLYMOUTH MEETING, Pa., April 27, 2021 /PRNewswire/ --INOVIO (NASDAQ: INO) announced today that first quarter 2021 financial results will be released after the market close on May 10, 2021.

Key Points: 
  • b'PLYMOUTH MEETING, Pa., April 27, 2021 /PRNewswire/ --INOVIO (NASDAQ: INO) announced today that first quarter 2021 financial results will be released after the market close on May 10, 2021.
  • Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m.
  • VGX-3100 also demonstrated positive Phase 2 efficacy results in separate trials evaluating the treatment of precancerousvulvar dysplasia and anal dysplasia.
  • INOVIO also is a proud recipient of 2020 Women on Boards "W" designation recognizing companies with more than 20% women on their board of directors.

Cervical Dysplasia Market Size Worth $936.4 Million By 2028 | CAGR: 7.5%: Polaris Market Research

Retrieved on: 
星期三, 三月 17, 2021
Infectious causes of cancer, Medical specialties, Histopathology, Oncology, Cervical intraepithelial neoplasia, Branches of biology, Cancer screening, Clinical medicine, Dysplasia, Gynaecological cancer

NEW YORK, March 17, 2021 /PRNewswire/ -- The global cervical dysplasia market size is expected to reach USD 936.4 million by 2028 according to a new study conducted by Polaris Market Research.

Key Points: 
  • NEW YORK, March 17, 2021 /PRNewswire/ -- The global cervical dysplasia market size is expected to reach USD 936.4 million by 2028 according to a new study conducted by Polaris Market Research.
  • Growing awareness about cervical dysplasia and the substantial rise in cancer screening programs in developing and developed countries helping the segment to grow.
  • Based on end-user, the hospital segment dominated the cervical dysplasia market and contributed the largest revenue share.
  • Feel Free to Ask Our Industry Experts at: https://www.polarismarketresearch.com/industry-analysis/cervical-dysplas...
    Polaris Market research has segmented the cervical dysplasia market report on the basis of type, end-use, and region:
    Cervical Dysplasia, by Type Outlook (Revenue USD Million, 2016 2028)

HealthWell Foundation Reopens Fund to Assist Medicare Patients Living with Myelodysplastic Syndromes

Retrieved on: 
星期一, 二月 22, 2021
Myelodysplastic syndrome, Health, Federal assistance in the United States, Healthcare reform in the United States, Presidency of Lyndon B. Johnson, Medicare, Medical specialties, Dysplasia, Clinical medicine

GERMANTOWN, Md., Feb. 22, 2021 /PRNewswire/ -- The HealthWell Foundation, an independent non-profit that provides a financial lifeline for inadequately insured Americans, has reopened a fund to provide medication copayment or insurance premium assistance to Medicare patients who are living with myelodysplastic syndromes (MDS).

Key Points: 
  • GERMANTOWN, Md., Feb. 22, 2021 /PRNewswire/ -- The HealthWell Foundation, an independent non-profit that provides a financial lifeline for inadequately insured Americans, has reopened a fund to provide medication copayment or insurance premium assistance to Medicare patients who are living with myelodysplastic syndromes (MDS).
  • "Patients living with myelodysplastic syndromes can suffer a multitude of symptoms including weakness, shortness of breath, and easy bruising or bleeding.
  • To determine eligibility and apply for financial assistance, visit HealthWell's Myelodysplastic Syndromes Medicare Access Fund page.
  • The Foundation provides answers, support, and hope to thousands of patients and their families around the world.

FibroGen to Present at Upcoming Investor Conferences

Retrieved on: 
星期五, 二月 12, 2021
Branches of biology, Biology, Cell biology, Transcription factors, Hypoxia-inducible factor, Growth factors, CTGF, Myelodysplastic syndrome, Roxadustat, Hypoxia in fish, HIF, Dysplasia

A replay will be available for approximately 30 days.

Key Points: 
  • A replay will be available for approximately 30 days.
  • FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics.
  • The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines for the treatment of unmet needs.
  • Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA).

FibroGen to Present Safety and Efficacy Analyses from Roxadustat Global Phase 3 Program at American Society of Hematology Annual Meeting

Retrieved on: 
星期三, 十二月 2, 2020
Clinical medicine, Medical specialties, Medicine, Oncology, Acetic acids, Isoquinolines, Roxadustat, Antineoplastic drugs, Anemias, Myelodysplastic syndrome, American Society of Hematology, Dysplasia

FibroGenand its partner will present eight abstracts at the 62ndAmerican Society of Hematology (ASH) Annual Meeting and Exposition, taking place virtually December 5-8, 2020.

Key Points: 
  • FibroGenand its partner will present eight abstracts at the 62ndAmerican Society of Hematology (ASH) Annual Meeting and Exposition, taking place virtually December 5-8, 2020.
  • In addition, we are presenting Phase 3 cardiovascular safety and efficacy results of roxadustat, which highlight its potential in a broad range of CKD patients.
  • As a HIF-PH inhibitor, roxadustat activates a response that occurs naturally when the body responds to reduced oxygen levels in the blood.
  • Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia (CIA).

FibroGen to Present at Upcoming Investor Conferences

Retrieved on: 
星期五, 十一月 6, 2020
Branches of biology, Biology, Cell biology, Transcription factors, Hypoxia-inducible factors, Growth factors, CTGF, Myelodysplastic syndrome, Roxadustat, Hypoxia in fish, HIF, Dysplasia

A replay will be available for approximately 30 days.

Key Points: 
  • A replay will be available for approximately 30 days.
  • FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing and commercializing a pipeline of first-in-class therapeutics.
  • The company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue growth factor (CTGF) biology to advance innovative medicines to treat unmet needs.
  • Roxadustat is also in clinical development for anemia associated with myelodysplastic syndromes (MDS) and for chemotherapy-induced anemia.